Company Description
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.
Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
| Country | United States |
| IPO Date | Jul 30, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 143 |
| CEO | Maher Masoud |
Contact Details
Address: 9713 Key West Avenue Rockville, Maryland United States | |
| Website | https://maxcyte.com |
Stock Details
| Ticker Symbol | MXCT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001287098 |
| CUSIP Number | 57777K106 |
| ISIN Number | US57777K1060 |
| Employer ID | 52-2210438 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Maher Masoud | President, Chief Executive Officer & Executive Director |
| Douglas J. Swirsky CFA, CPA | Chief Financial Officer |
| David Sandoval | Senior Vice President, General Counsel & Corporate Secretary |
| Douglas Arthur Doerfler | Founder |
| Dr. J. Stark Thompson Ph.D. | Consultant |
| Jack Horgan | Vice President of Corporate Development |
| Jay Gelfman | Senior Vice President of Operations |
| Jill Mayer | Senior Vice President of Human Resources |
| Ronald Evan Holtz CPA, Ph.D. | Executive Vice President of Administration |
| Thomas Michael Ross | Executive Vice President of Global Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 4 | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 30, 2024 | 4 | Filing |
| Dec 27, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 4 | Filing |
| Dec 09, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 10-Q | Quarterly Report |
| Nov 06, 2024 | 8-K | Current Report |